I stumbled upon a fascinating piece of research from Iceland that looked at the role of Circadian Disruption in Prostate Cancer Development. Knowing my own very poor sleeping patterns and having heard many other men with advanced prostate cancer complaining about very similar experiences it peaked my interest. The researchers pointed out that there have [...]
Provenge, despite its demonstrated survival advantage, continues to be knocked as a viable treatment for men with castrate-resistant prostate cancer. What is Provenge? Provenge is immunotherapy for men with metastatic castrate-resistant prostate cancer. In other words, Provenge might help men live longer after their cancer has spread outside of the prostate and are no [...]
JAMA Oncology has published a new study that suggests that adding a statin drug at the initiation of hormone therapy (ADT) to the treatment protocol for a man with progressive, hormone-sensitive prostate cancer may significantly impact their actual time to disease progression (TTP). Historically, we know Statin use has been associated with improved prostate cancer [...]
A recently previewed (prior to the upcoming ASCO Annual Meeting) of a large study shows that men with prostate cancer who had a PSA-based relapse (Biochemical Recurrence) could delay starting androgen deprivation therapy (ADT) until they started experiencing symptoms from the cancer. They found that this delay would not affect the men’s long-term survival. The [...]